SUMMARY Chronic congestive heart failure not controlled by conventional therapy was treated with intravenous amrinone, a new non-glycosidic, non-catecholamine cardiotonic agent. Eight patients with New York Heart Association functional class III-IV symptoms were hemodynamically monitored. At peak effect, cardiac index (CI) increased from 1.84 ± 0.32 to 2.74 0.44 1/min/m2 (mean ± SD) (p < 0.001) and left ventricular filling pressure (LVFP) decreased from 25.8 6.2 to 19.5 ± 6.8 mm Hg (p < 0.05), while heart rate and mean aortic blood pressure did not change significantly. Mean endocardial circumferential fiber shortening (mean Vcf), determined by echocardiography, increased from 0.61 ± 0.27 to 0.89 ± 0.34 circ/sec (p < 0.05). The duration of action after bolus infusion varied from 60-90 minutes. During continuous infusion of amrinone, sustained increases in CI and reductions in LVFP, similar to those at the time of peak effect after bolus administration, were maintained for 180 minutes. These marked cardiotonic effects of amrinone in patients already taking digitalis for severe heart failure occurred without side effects of arrhythmias or altered arterial pressures. The fact that the drug is orally active makes amrinone a very promising inotropic agent for the treatment of chronic heart failure in man.
HEART FAILURE resulting from depression of myocardial contractility is generally not adequately treated. Despite recent emphasis on the use of vasodilators to improve ventricular performance by reducing the load on the heart, pharmacologic therapy of pump failure continues to rely heavily on augmenting contractility of depressed cardiac muscle with inotropic agents. However, inotropic agents are limited in their usefulness due primarily to their toxic side effects or restricted modes of administration. Digitalis glycosides, which have been available for nearly 200 years, increase the force of cardiac contraction in both normal and failing heart muscle.1 However, cardiac glycosides are not always beneficial hemodynamically in patients with chronic cardiac failure due to cardiomyopathy or coronary artery disease,2 and increased doses are commonly limited by toxic side effects. Catecholamines exert a positive inotropic effect by stimulating cardiac #, receptors, but their usefulness is limited by harmful tachycardias, potentially malignant arrhythmias, undesirable increases or decreases in arterial pressure, and a general requirement for intravenous administration.3
Amrinone, a bipyridine derivative* ( fig. 1) synthesized by G.Y. Lesher and C.J. Opalka of the Sterling-Winthrop Laboratories, has recently been shown to be cardioactive in both in vitro and in vivo experiments in animals.4 In in vitro studies, amrinone increased the force of contraction of atrial and ventricular muscle without increasing spontaneous right atrial rate. In in vivo experiments in dogs, it increased cardiac output while reducing ventricular filling pressures. Neither arterial pressure nor heart rate changed significantly. The drug was active both orally and intravenously, and did not produce arrhythmias, even at high doses4' (Alousi AA, Farah AE, Lesher GY, Opalka CJ Jr: unpublished data). Toxicity in animals consisted solely of modest diastolic hypotension seen at very elevated dose levels. Preliminary studies indicate that the cardiotonic action of amrinone is not attributable to the mechanisms thought to mediate the action of either glycosides or catecholamines.4 5 Thus, Na+ -K+ ATPase activity is not inhibited as it is by glycosides. Amrinone actions are not prevented by ,B-adrenergic blockade; nor are they diminished when catecholamine stores in the heart are depleted (Alousi AA, Farah AE, Lesher GY, Opalka CJ Jr: unpublished data). Neither adenosine-3', 5'-monophosphate levels nor phosphodiesterase activity are altered by the drug.
The non-glycosidic, non-catecholamine nature of amrinone, its oral effectiveness, and lack of significant experimental toxicity make it potentially important for clinical use as a cardiotonic agent in the therapy of human myocardial failure. Initial studies in normal, healthy men in which the drug was given intravenously have indicated positive inotropic activity on the basis of ejection time indices.6 We report the first beneficial use of amrinone for the treatment of heart failure in man.
Methods

Subjects
Amrinone therapy was offered to patients in whom 1098 congestive heart failure was not controlled by conventional treatment with digitalis and diuretics. The nature, potential benefits, and possible risks of the study were fully explained to the patients, who then gave informed consent. The protocol was approved by the Committee on Clinical Investigations of the Albert Einstein College of Medicine. Eight patients, four female and four male, comprised the study group. All patients suffered from symptoms of fatigue and dyspnea sufficient to place them in class 111-IV of the New York Heart Association classification. Complete cardiac catheterization with coronary and left ventricular angiography confirmed ventricular enlargement, elevated end-diastolic ventricular pressure, and reduced ejection fraction in each subject. The clinical and diagnostic information are summarized in table 1. No patient had primary valve disease, hypertension, recent myocardial infarction or active ischemia at the time of the study. The cardiac rhythm was sinus in six patients and atrial fibrillation in one; in the eighth patient, a demand ventricular pacemaker had been implanted for sinus node dysfunction during an earlier admission. All subjects were fully digitalized (table 1) and continued to take their usual doses of digoxin and diuretics throughout the study. Several patients had taken vasodilators previously, with minimal benefit; these drugs were discontinued at least 1 week before administration of amrinone. 6.4 P NS NS Abbreviations: HF = heart failure; LVEDP -left ventricular end-diastolic pressure; LVDVI = left ventricular diastolic volume index; HRI = heart rate; MAP = mean arterial pressure; CI = cardiac index; PCW = pulmonary capillary wedge pressure; MPAP = mean pulmonary artery pressutre; RAP = right atrial pressure; SVR = systermic vascular resistance; PVR pulmonary vascular resistance; C = control; A = amrinone; CAD = coronlary artery disease.
Institute, Rensselaer, New York), diluted in normal saline, was administered intravenously at a rate of 1 mg/sec. Hemodynamic determinations were obtained at 5-, 10-, 20-, 60-, and 90-minute intervals after the injection or until a return to control. The procedure was then repeated on successive days at progressively higher doses. In the first two patients, the initial bolus dosage was 0.25 mg/kg body weight, with increments of 0.25 mg/kg/day to a maximum bolus dosage of 0.75 and 1.5 mg/kg, respectively. After the experience with these two patients revealed no significant change in HR or arterial pressure, the starting dosage was increased to 0.75 mg/kg and the daily dosage increment was raised to 0.5 or 0.75 mg/kg, depending on the control LVFP and the response to the initial 0.75 mg/kg bolus. When the total dose per injection exceeded 1.5 mg/kg body weight, the rate of administration was slowed to 0.5 mg/sec. In the last six subjects, the maximum amount of amrinone administered in a single bolus was 2.5 mg/kg, except for one patient who received 3 mg/kg. However, at any dosage level, a fall in the LVFP to or below 10 mm Hg was considered a contraindication to raising the dose. To determine whether sustained hemodynamic benefit would result, a continuous infusion of amrinone was initiated concomitantly with the bolus injection in three patients. The rate of infusion varied from 6-10 qg/kg/min, with a duration of 10 hours. dyn-sec-cm-5 (p < 0.001) and mean PVR fell from 345 ± 133 to 211 ± 80 dyn-sec-cm-5 (p < 0.05). As expected, mean SVI increased from 25.8 ± 3.1 to 36.9 ± 5.1 ml/m2 (p < 0.01). Individual changes in SVI are plotted as a function of LVFP in figure 3. Reduction of LVFP was uniformly associated with an augmentation of the SVI. This shift upward and to the left is consistent with an improvement of left ventricular function in all patients.
In every instance, the peak increase occurred 2-10 minutes after administration of the drug, as shown in figure 4. Cardiac index was significantly increased at 10 and 30 minutes after the bolus of intravenous amrinone, while PCW pressure was significantly reduced as long as 90 minutes after the drug administration. The hemodynamic mechanisms of action of amrinone to produce the beneficial effects are complex. The effects to decrease LVFP while augmenting CO and Vcf can result from either an increase in myocardial contractility or a decrease in impedance to ventricular ejection or both. The former effect is supported in dog experiments in which direct measurements of contractile force and left ventricular rate of pressure development (dp/dt) were shown to rise.5 Preliminary studies in two patients in our laboratory demonstrated a similar increase in left ventricular dp/dt despite a decrease in left ventricular enddiastolic pressure. The latter effect of decreasing arterial impedance also occurred, with a decrease in SVR, i.e., CO rose while MAP was unchanged. This could also have contributed to an increase in ejection fraction and reduced diastolic ventricular pressures, but would not have augmented left ventricular dp/dt. Thus, we would conclude that the effects of amrinone were the result of both an increase in cardiac contractility and a decrease in peripheral arterial resistance.
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The vasodilatory effects of amrinone may be mediated directly by action on the systemic arteriolar bed and indirectly by withdrawal of heightened sympathetic tone in the presence of severe heart failure. The direct vasodilatory effects of amrinone are suggested from studies in normal dogs in which very high doses of amrinone induced hypotension.5 No such reductions in arterial pressure were noted with the doses of the drug used in the present investigation. Indirect withdrawal of sympathetic tone to reduce SVR resulting from improved cardiac contractility probably occurred in our patients with severe failure in a manner similar to that observed after administration of digitalis glycoside under similar conditions.8
All of our patients experienced a significant fall in LVFP. Although these reductions could be mediated by improvement in contractility with enhanced systolic emptying of the left ventricle, the marked decreases in LVFP in three patients strongly suggest that amrinone may also produce direct venodilatation. As suggested by the results in two of these patients, an excessive reduction in LVFP may limit the ability of the drug to further increase CI.
The activity of amrinone was dose-dependent, although the glycosides or catecholamines.4 5 Whether amrinone affects excitation-contraction coupling directly or modifies interactions of contractile protein is unknown. All inotropic agents are thought to affect contraction by making more calcium available to the myofilaments. Whether this is true for amrinone and how it is mediated remains to be defined. The fact that amrinone augments myocardial contractility in patients who are already fully digitalized supports the view that residual contractile reserve can be mobilized in the severely failing heart.
Our data indicate that amrinone may be very beneficial in the treatment of heart failure in man. Further studies are in progress to define the specific use of oral amrinone in the long-term therapy of this disease. 
